We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals

199 hedge funds and large institutions have $2.04B invested in Recursion Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 69 increasing their positions, 47 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

941% more capital inflows, than outflows

Capital inflows: $433M | Capital outflows: $41.6M

105% more call options, than puts

Call options by funds: $8.93M | Put options by funds: $4.34M

47% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 47

29% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 34

24.57% more ownership

Funds ownership: 74.62% → 99.19% (+25%)

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

4% more funds holding

Funds holding: 191 → 199 (+8)

Holders
199
Holders Change
+8
Holders Change %
+4.19%
% of All Funds
2.89%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.09%
New
44
Increased
69
Reduced
47
Closed
34
Calls
$8.93​M
Puts
$4.34​M
Net Calls
+$4.58​M
Net Calls Change
+$4.79​M

RXRX Hedge Fund Activity: Q4 2023 in Review

199 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2023, worth a combined $2.04B — up 75% from $1.16B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new RXRX positions and 34 closed out — a net gain of 10 holders — while 69 added to existing stakes and 47 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $98.2M. The largest seller was ArchPoint Investors, exiting entirely with an estimated $8.01M sold.

  • 199 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2023, up from 191 in Q3 2023.
  • Funds reported $2.04B of Recursion Pharmaceuticals stock for Q4 2023, up 75% quarter-over-quarter.
  • 44 funds opened new Recursion Pharmaceuticals positions in Q4 2023 and 34 closed out, a net change of +10 holders.
  • The largest Recursion Pharmaceuticals buyer in Q4 2023 was ARK Investment Management, an estimated $98.2M added.
  • The largest Recursion Pharmaceuticals seller in Q4 2023 was ArchPoint Investors, an estimated $8.01M sold.

Based on aggregated 13F filings for Q4 2023.